Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Vaneck Biotech ETF
(NQ:
BBH
)
181.74
+0.94 (+0.52%)
Official Closing Price
Updated: 4:15 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaneck Biotech ETF
VanEck Announces Year-End Distributions for VanEck Equity ETFs
December 15, 2023
From
VanEck
Via
Business Wire
Time For Gilead Sciences-Heavy ETFs?
September 12, 2023
Gilead Sciences has underperformed the broader market this year by a hefty margin.
Via
Talk Markets
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
April 13, 2023
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...
Via
Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
April 13, 2023
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Via
Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
April 12, 2023
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...
Via
Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
April 11, 2023
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...
Via
Benzinga
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
April 06, 2023
Via
Benzinga
VanEck Launches Robotics ETF (IBOT)
April 06, 2023
From
VanEck
Via
Business Wire
US Judge Weighs Nationwide Ban On Abortion Pills
March 16, 2023
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...
Via
Benzinga
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
March 01, 2023
Via
Benzinga
3 Best Funds for Aggressive Investors
August 11, 2022
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year.
Via
InvestorPlace
Progenity Is Unlikely to Live Up to Its IPO Hype
December 15, 2021
Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech?
Via
InvestorPlace
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
June 22, 2022
With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in.
Via
InvestorPlace
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
November 01, 2021
After the formidable run, NVAX stock has come under significant pressure, but between its pipeline and its Covid vaccine, it is a dip buy.
Via
InvestorPlace
Take A Look At The Top-Performing Biotech ETFs YTD
October 02, 2021
The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq...
Via
Talk Markets
Exposures
COVID-19
Biotech ETFs To Benefit From Latest Booster Update
August 21, 2021
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from...
Via
Talk Markets
Exposures
COVID-19
ETF Investing Areas to Consider for August
August 09, 2021
There is no doubt that the second-quarter 2021 earnings season is going strong.
Via
Talk Markets
Moderna ETFs To Rise On Positive COVID-19 Vaccine Updates
July 03, 2021
The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to...
Via
Talk Markets
Exposures
COVID-19
5 Top ETFs With Exposure To Biogen
June 07, 2021
Here is a look at five ETFs with large exposure to Biogen shares.
Via
Talk Markets
5 Top ETFs With Exposure To Biogen
June 07, 2021
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...
Via
Benzinga
Exposures
Product Safety
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
May 08, 2021
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from...
Via
Talk Markets
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Stock Moves After Q1 Print: Technical Levels For The COVID-19 Vaccine Play
May 06, 2021
Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the...
Via
Benzinga
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.